萧条(经济学)
医学
难治性抑郁症
精神科
抗抑郁药
经济
焦虑
宏观经济学
作者
NULL AUTHOR_ID,Kirti Saxena,NULL AUTHOR_ID,NULL AUTHOR_ID,NULL AUTHOR_ID,Asim A. Shah
出处
期刊:Psychiatric Annals
[SLACK, Inc.]
日期:2024-06-01
卷期号:54 (6)
标识
DOI:10.3928/00485713-20240618-04
摘要
The management of treatment-resistant depression (TRD) is challenging. Researchers have identified novel targets, especially the glutamatergic system, in the pathogenesis of depressive disorder. N-methyl-D-aspartate (NMDA) receptor antagonists, like ketamine, have revolutionized the treatment of TRD due to their rapid antidepressant and antisuicidal effect. Various other receptor systems, including GABAergic, opioid receptors, the endogenous cannabinoid system, and cholinergic receptors, are novel targets to produce an antidepressant response. The US Food and Drug Administration (FDA) has approved intra-nasal ketamine as an add-on therapy to conventional antidepressants for TRD. Other compounds are in various stages of development. Identification and development of novel compounds by future research can help in overcoming the challenges of treating TRD. [ Psychiatr Ann . 2024;54(6):e177–e181.]
科研通智能强力驱动
Strongly Powered by AbleSci AI